empty

Clinical

Biosimilars on the menu for moderate rheumatoid arthritis

NICE guidance previously recommended biologics only for severe RA.

NICE recommends mental health support for people with acne

Mental health support is key in managing acne vulgaris, says clinical watchdog.

Antidepressants prescribed twice as much in deprived areas

Antidepressant drugs were prescribed to more than twice as many people in the most deprived parts of England compared to the least in 2020-21. 

Discontinuing statins may increase CV risk

Discontinuing statins in people on multiple medications may increase the risk of fatal and non- fatal cardiovascular outcomes, a study shows. 

Statins may reduce cancer risk in HF

Statins may significantly reduce the risk of cancer and cancer-related death in people with heart failure, according to a new study.

Up to 2 million people may have had long Covid

Persistent symptoms increase with age, are higher among women but lower in people of Asian ethnicity

Warning of myocarditis and pericarditis risk with Covid vaccines

Product information updated for Pfizer/BioNTech and Moderna vaccines - insufficient evidence to justify new warning for AZ vaccine.

NICE approves secukinumab for chronic pain condition

NICE has recommended the use of secukinumab as an option for treating a chronic back pain condition affecting young adults.

The long wait for a diabetes diagnosis

On average patients live with type 2 diabetes for more than two years before being diagnosed, according to new research.

Atopic dermatitis linked to learning disabilities

Atopic dermatitis (AD) shows a "dose-dependent association" with learning disability, American researchers report.

New advice for patients switching between levothyroxine products

Small number have reported symptoms consistent with thyroid dysfunction when their tablets were changed to a different product.

Covid-19 vaccine booster study launches in UK

Initial results from trialling seven vaccines are expected in September to inform plans for a booster programme.

Antihypertensives prevent CVD even when BP normal

Antihypertensives can prevent serious cardiovascular disease (CVD) even among adults with normal blood pressure, new research suggests. 

Lung health taskforce asks public to share data

The Taskforce for Lung Health is aiming to raise awareness of the launch of its Lung Health Data Tracker.

NICE recommends new drug for relapsing MS

NICE has recommended the use of auto-injectable MS drug ofatumumab on the NHS. 

More people could benefit from antihypertensives, study finds

Many more people could benefit from blood pressure-lowering medication, according to a new study in the Lancet.

Lack of sleep increases dementia risk by 30 per cent

People who continuously sleep for six hours or less a night are roughly 30 per cent more likely to develop dementia.

'Urgent need' for evidence on discontinuing antidepressants

There is an "urgent need" for better evidence on the safest and most effective ways to discontinue antidepressants, a review finds. 

Asthma drug shortens at-home recovery from Covid-19

Early treatment with inhaled budesonide shortens recovery time among Covid-19 patients being treated in the community, PRINCIPLE has shown. 

MHRA approves self-inject treatment for relapsing MS

The MHRA has approved ofatumumab for adult patients with relapsing forms of multiple sclerosis (RMS), manufacturer Novartis has announced. 

Previous 1 2 3 4 5 ... 9 Next


This website is for healthcare professionals, people who work in pharmacy and pharmacy students. By clicking into any content, you confirm this describes you and that you agree to Pharmacy Network News's Terms of Use and Privacy Policy.

We use essential, performance, functional and advertising cookies to give you a better web experience. Find out how to manage these cookies here. We also use Interest Based Advertising Cookies to display relevant advertisements on this and other websites based on your viewing behaviour. By clicking "Accept" you agree to the use of these Cookies and our Cookie Policy.